Lumos Pharma Q1 2024 GAAP EPS $(1.29) Misses $(1.18) Estimate, Sales $165.00K Miss $302.60K Estimate
Portfolio Pulse from Benzinga Newsdesk
Lumos Pharma (LUMO) reported Q1 2024 GAAP EPS of $(1.29), missing the $(1.18) estimate, with sales of $165.00K also missing the $302.60K estimate, marking a 76.12% decrease from the same period last year.

May 14, 2024 | 8:53 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lumos Pharma's Q1 2024 earnings and sales significantly missed analyst estimates, with a notable year-over-year sales decrease.
Missing both EPS and sales estimates significantly, especially with a sharp year-over-year sales decline, typically leads to negative investor sentiment and could result in a short-term stock price decline.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100